Education
About Us
Working with TipRanks
Follow Us
Doximity (DOCS)
NYSE:DOCS
DOCS Analyst Ratings
Moderate Buy
8 Buy
5 Hold
2 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
DOCS Stock 12 Month Forecast
Average Price Target
$70.31
▲(33.36% Upside)
| Highest Price Target$82.00 | Average Price Target$70.31 | Lowest Price Target$58.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Truist Financial
―
Hold
―
Reiterated
11/11/25
Canaccord Genuity
$67→$58
Hold
10.02%
Upside
Reiterated
11/10/25
Mizuho Securities
$60→$62
Hold
17.60%
Upside
Reiterated
11/10/25
TR | OpenAI - 4o
$69
Buy
30.88%
Upside
Reiterated
11/08/25
AI Generated ArticleAI Generated Article
Bank of America Securities
$82
Buy
55.54%
Upside
Reiterated
11/07/25
William Blair
―
Buy
―
Reiterated
11/07/25
Doximity's Strong Financial Performance and Strategic Positioning Justify Buy RatingWe recommend investors continue to accumulate shares of DOCS following strong second quarter 2026 results, especially on any pullbacks. Consistentwith Doximity’s year-to-date performance, our recent industry conversations also point to healthy year-to-date pharma marketing spending despite some modest risk to budgets into year-end given broader end-market uncertainty (e.g., FDA headcount reductions, potential tariffs, discussion of pricing regulations). Moreover, despite this noise, we believe the company continues to experience strong underlying growth, particularly with recently launched products and novel AI-based physician workflow tools (where users grew 50% sequentially).
Morgan Stanley
$62
Hold
17.60%
Upside
Reiterated
11/07/25
Needham
$75
Buy
42.26%
Upside
Reiterated
11/07/25
Evercore ISI
$81→$70
Buy
32.78%
Upside
Reiterated
11/07/25
Wells Fargo
$65
Hold
23.29%
Upside
Assigned
11/06/25
Doximity's Hold Rating: Balancing Short-Term Gains with Long-Term Uncertainty Amid Competitive PressuresWe move our estimates to top end of guide for F2Q & FY26; our confidence bolstered by what we still view as a low hurdle for a beat & raise, positive KOL read-throughs (link), consistency of FDA's novel drug approval cadence (34 YTD vs 38 YTD in 2024; Exhibit 4, herein), and a sequentially upward trajectory in MAUs over the last 4 months (Exhibit 1; encouraging trends that are likely to bolster net dollar retention). F2Q earnings 11/06 AH. Resumption of MAU growth after two years of horizontal movement... Higher HCP engagement can help support more ad spend, all else equal. MAU trends likely benefiting from debut of Doximity's AI scribe and its PathwayMD acquisition.
J.P. Morgan
$62
Sell
17.60%
Upside
Downgraded
10/14/25
KeyBanc
$75→$80
Buy
51.75%
Upside
Reiterated
10/08/25
Raymond James
$75
Buy
42.26%
Upside
Reiterated
10/03/25
Goldman Sachs
$57→$64
Sell
21.40%
Upside
Downgraded
10/01/25
Robert W. Baird
$75→$80
Buy
51.75%
Upside
Reiterated
09/11/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Truist Financial
―
Hold
―
Reiterated
11/11/25
Canaccord Genuity
$67→$58
Hold
10.02%
Upside
Reiterated
11/10/25
Mizuho Securities
$60→$62
Hold
17.60%
Upside
Reiterated
11/10/25
TR | OpenAI - 4o
$69
Buy
30.88%
Upside
Reiterated
11/08/25
AI Generated ArticleAI Generated Article
Bank of America Securities
$82
Buy
55.54%
Upside
Reiterated
11/07/25
William Blair
―
Buy
―
Reiterated
11/07/25
Doximity's Strong Financial Performance and Strategic Positioning Justify Buy RatingWe recommend investors continue to accumulate shares of DOCS following strong second quarter 2026 results, especially on any pullbacks. Consistentwith Doximity’s year-to-date performance, our recent industry conversations also point to healthy year-to-date pharma marketing spending despite some modest risk to budgets into year-end given broader end-market uncertainty (e.g., FDA headcount reductions, potential tariffs, discussion of pricing regulations). Moreover, despite this noise, we believe the company continues to experience strong underlying growth, particularly with recently launched products and novel AI-based physician workflow tools (where users grew 50% sequentially).
Morgan Stanley
$62
Hold
17.60%
Upside
Reiterated
11/07/25
Needham
$75
Buy
42.26%
Upside
Reiterated
11/07/25
Evercore ISI
$81→$70
Buy
32.78%
Upside
Reiterated
11/07/25
Wells Fargo
$65
Hold
23.29%
Upside
Assigned
11/06/25
Doximity's Hold Rating: Balancing Short-Term Gains with Long-Term Uncertainty Amid Competitive PressuresWe move our estimates to top end of guide for F2Q & FY26; our confidence bolstered by what we still view as a low hurdle for a beat & raise, positive KOL read-throughs (link), consistency of FDA's novel drug approval cadence (34 YTD vs 38 YTD in 2024; Exhibit 4, herein), and a sequentially upward trajectory in MAUs over the last 4 months (Exhibit 1; encouraging trends that are likely to bolster net dollar retention). F2Q earnings 11/06 AH. Resumption of MAU growth after two years of horizontal movement... Higher HCP engagement can help support more ad spend, all else equal. MAU trends likely benefiting from debut of Doximity's AI scribe and its PathwayMD acquisition.
J.P. Morgan
$62
Sell
17.60%
Upside
Downgraded
10/14/25
KeyBanc
$75→$80
Buy
51.75%
Upside
Reiterated
10/08/25
Raymond James
$75
Buy
42.26%
Upside
Reiterated
10/03/25
Goldman Sachs
$57→$64
Sell
21.40%
Upside
Downgraded
10/01/25
Robert W. Baird
$75→$80
Buy
51.75%
Upside
Reiterated
09/11/25
Best Analysts Covering Doximity
1 Month
xxx
Success Rate
7/10 ratings generated profit
Average Return
+1.05%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 70.00% of your transactions generating a profit, with an average return of +1.05% per trade.
3 Months
xxx
Success Rate
8/10 ratings generated profit
Average Return
+12.56%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +12.56% per trade.
1 Year
Success Rate
8/10 ratings generated profit
Average Return
+12.68%
reiterated a buy rating 5 days ago
Copying Isla Carelynx 's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +12.68% per trade.
2 Years
xxx
Success Rate
8/10 ratings generated profit
Average Return
+12.68%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +12.68% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
DOCS Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
1
1
0
0
1
Buy
14
20
19
23
14
Hold
20
18
16
13
10
Sell
0
0
0
3
3
Strong Sell
0
0
0
0
0
total
35
39
35
39
28
Each month's total comprises the sum of three months' worth of ratings.
DOCS Financial Forecast
DOCS Stock Forecast FAQ
What is DOCS’s average 12-month price target, according to analysts?
Based on analyst ratings, Doximity’s 12-month average price target is 70.31.
What is DOCS’s upside potential, based on the analysts’ average price target?
Doximity has 33.36% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is DOCS a Buy, Sell or Hold?
Doximity has a consensus rating of Moderate Buy which is based on 8 buy ratings, 5 hold ratings and 2 sell ratings.
What is Doximity’s price target?
The average price target for Doximity is 70.31. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $82.00 ,the lowest forecast is $58.00. The average price target represents 33.36% Increase from the current price of $52.72.
The highest analyst price target is $82.00 ,the lowest forecast is $58.00. The average price target represents 33.36% Increase from the current price of $52.72.
What do analysts say about Doximity?
Doximity’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.
How can I buy shares of DOCS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.